Champignon Brands Also Announced it Has Filed an Application With the BCSC and OSC to Revoke Their Cease Trade Orders
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced on Friday that the company has filed its new listing statement with the Canadian Securities Exchange (CSE). Included in the new CSE listing statement are disclosures pertaining to the AltMed acquisition, which constituted a reverse takeover of Champignon by AltMed.
In addition, Champignon also reported that it filed an application with the British Columbia Securities Commission (BCSC) and Ontario Securities Commission (OSC) officially requesting the revocation of the regulatory commissions’ cease trade orders against the company.
A cease trade order was placed on Champignon’s common shares by the commissions for the following reasons:
- Content deficiency in the company’s material change report dated April 30, 2020
- Failure to provide periodic financial disclosure for the interim period ended June 30, 2020
On March 11, 2021, Champignon Brands filed (or refiled, as applicable) the company’s interim financial statements and management’s discussion & analysis (MD&A) for the interim periods ending March 31, 2020, June 30, 2020, and September 30, 2020, respectively, as previously announced on March 11, 2021.
On March 15, 2021, the company filed a Notice of Change in Corporate Structure Pursuant to Part 4 of National Instrument 51–102 – Continuous Disclosure Obligations and on March 22, 2021, Champignon filed interim financial statements and management’s discussion & analysis for the period ended December 31, 2020.
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) is a medical solutions company that aims to reduce the illness burden of brain-based mental disorders (e.g., major depressive disorder). Its operations are primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
Champignon develops ketamine and psilocybin derivatives and other psychedelic products from the Company’s IP development platform. Champignon, through its wholly-owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto and Ottawa.
This U.S. Cannabis Stock Appears to Be Way Undervalued and May Actually Benefit From a Second Wave of the Pandemic
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.